Table 2.

Baseline and post-treatment characteristics of the immunosuppression treatment patients. Human herpes virus 6, HHV6; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NYHA, New York Heart Failure Association functional class; ND, not detected.

Patient #	1	2	3	4	5	6	7	8	9	10
Age	51	29	57	33	33	38	20	48	19	31
Sex	male	female	male	male	male	male	male	female	male	male
HHV6 type	B	B	B	B	B	B	B	B	B	B
HHV6-DNA copy number before treatment	33	46	417	1	34	35	1	1	19	1
HHV6-DNA copy number after treatment	408	0	0	57	0	0	0	0	0	0
HHV6-DNA presence in PBMCs before treatment	0	0	0	+	0	+	0	0	+	0
HHV6-DNA presence in PBMCs after treatent	0	0	0	0	0	0	0	0	0	0
LVEF before treatment (%)	40	60	27	60	18	37	50	50	59	18
LVEF after treatment (%)	45	50	50	60	33	43	57	50	76	30
LVEDD before treatment (mm)	64	54	67	44	83	62	46	53	47	46
LVEDD after treatment (mm)	63	53	60	47	75	65	50	55	56	63
NYHA class before treatment	2	2	3	2	4	3	2	3	1	2
NYHA class after treatment	2	2	2	1	2	3	2	2	1	2
Grade of inflammation before treatment	I	II	II	II	I	II	II	II	II	II
Grade of inflammation after treatment	I	I	II	ND	ND	II	ND	I	ND	ND